Shenzhen-based vascular intervention specialist OrbusNeich Medical Group Ltd (HKG: 6929) has announced a significant distribution agreement with Cardiovascular Systems Inc. (CSI), a subsidiary of U.S. giant Abbott Laboratories (NYSE: ABT). Under this agreement, CSI will serve as the exclusive distributor of OrbusNeich’s coronary and peripheral balloon products in the United States until December 31, 2027. Specific financial terms of the deal remain undisclosed.
Expanding Access to Innovative Vascular Solutions
CSI, a recognized leader in medical devices for peripheral and coronary artery diseases, offers a range of specialized products, including its peripheral plaque circumcision system and coronary artery plaque circumcision system, along with associated circumcision heads and accessories. This partnership aims to enhance the availability of OrbusNeich’s innovative balloon products in the U.S. market, furthering advancements in vascular intervention.
Strategic Collaboration to Improve Patient Outcomes
The collaboration between OrbusNeich and CSI is expected to enhance both companies’ strengths in delivering cutting-edge vascular therapies. By combining OrbusNeich’s expertise in balloon technology with CSI’s established distribution network, they aim to improve patient outcomes in the management of coronary and peripheral artery diseases.-Fineline Info & Tech
